This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of VA106483 in Elderly Males

This study has been completed.
Veeda Clinical Research
Information provided by:
Vantia Ltd Identifier:
First received: February 18, 2009
Last updated: April 8, 2009
Last verified: April 2009
A double blind, placebo-controlled, dose ranging study in males over the age of 65, who have a history of nocturia. The study will investigate pharmacodynamic outcomes (urine volumes and osmolality, circulating coagulation factors and haemodynamics) and pharmacokinetics, of both single and multiple oral doses of VA106483 at three dose levels, under conditions of controlled hydration.

Condition Intervention Phase
Nocturia Drug: VA106483 Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Official Title: A Double-Blind, Placebo-Controlled Dose Response Study to Investigate Pharmacodynamics and Pharmacokinetics of Single and Repeated Oral Doses of VA106483 in Elderly Male Subjects

Further study details as provided by Vantia Ltd:

Primary Outcome Measures:
  • Pharmacodynamic profile of VA106483

Secondary Outcome Measures:
  • Pharmacokinetic profile of VA106483
  • Safety and tolerability of VA106483

Enrollment: 27
Study Start Date: August 2008
Detailed Description:
VA106483 is a selective vasopressin V2 receptor agonist which is currently under development for the treatment of nocturia in males. This study examines the pharmacological action of VA106483 on markers of clinical efficacy (urine volumes and osmolality) and safety markers (coagulation factors and haemodynamics). The study will also assess the pharmacokinetics in the study population. The study design includes both cross-over and parallel phases so that pharmacodynamic and pharmacokinetic parameters can be assessed following both single and repeat dosing. Three dose levels will be given.

Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males 65 years and above with history of nocturia

Exclusion Criteria:

  • Any clinically significant concomitant medical disease, condition or abnormal laboratory test result
  • Participation in any other clinical study within 30 days
  • Intake of non-prescription medication within 14 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00879138

United Kingdom
Veeda Clinical Research
Plymouth, United Kingdom
Sponsors and Collaborators
Vantia Ltd
Veeda Clinical Research
  More Information Identifier: NCT00879138     History of Changes
Other Study ID Numbers: 483-001
Study First Received: February 18, 2009
Last Updated: April 8, 2009

Additional relevant MeSH terms:
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms processed this record on September 21, 2017